Acute management of unstable angina and non-ST segment elevation myocardial infarction

Morita, Fernando; Pesaro, Antônio Eduardo Pereira; Franken, Marcelo; Wajngarten, Maurı́cio

doi:10.1590/s1679-45082015rw3172

Cited by 21 publications

(19 citation statements)

References 32 publications

(60 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…UAP is associated with higher risk of acute myocardial infarction and sudden death. The current therapeutic strategy of angina pectoris mainly includes anti-ischemia, anti-thrombosis, and anti-platelet or revascularization procedures (Parikh and Kadowitz, 2014;Silva et al, 2015).…”

Section: Introductionmentioning

confidence: 99%

Dazhu Hongjingtian Preparation as Adjuvant Therapy for Unstable Angina Pectoris: A Meta-Analysis of Randomized Controlled Trials

2020

View full text Add to dashboard Cite

Objective: Dazhu hongjingtian [DZHJT, Rhodiola wallichiana var. cholaensis (Praeger) S.H. Fu] preparation as an add-on therapy has been applied to the treatment of angina pectoris. We aimed to evaluate the efficacy and safety of DZHJT as adjuvant therapy for the treatment of unstable angina pectoris (UAP). Methods: An extensive literature search was conducted on PubMed, Emase, Cochrane Library, Wanfang, CNKI, and VIP databases from inception to January 2019. Randomized controlled trials (RCTs) comparing DZHJT in combination with Western medicine with Western medicine alone were included. Two authors independently performed the literature search, data extraction and risk of bias assessment of included studies, and conducted the statistical analysis. Results: A total of 18 RCTs involving 1,679 patients were included in the meta-analysis. Adjuvant treatment with DZHJT significantly decreased ≥80% reduction in the frequency of angina attacks [risk ratio (RR) 1.57; 95% CI 1.36-1.81], weekly frequency of angina attacks [mean difference (MD) −1.03 times; 95% confidence interval (CI) −1.51 to −0.55], marked improved abnormal electrocardiogram (RR 1.46; 95% CI 1.23-1.74). In addition, DZHJT significantly reduced the whole-blood viscosity (MD −0.70 mPa.s; 95% CI −0.84 to −0.55), plasma viscosity (MD −0.28 mPa.s; 95% CI −0.38 to −0.19), serum level of fibrinogen (MD −0.67 g/L; 95% CI −0.79 to −0.54), thromboxanes B2 (MD −14.01 ng/L; 95% CI −20.86 to −7.15), and C-reactive protein (MD −1.48 mg/L; 95% CI −2.72 to −0.25). No significant differences in headache/dizziness (RR 0.72; 95% CI 0.31-1.67) were observed between two groups. Conclusion: Adjuvant treatment with DZHJT has an add-on effect in reducing angina pectoris attacks in patients with UAP. The beneficial effect may be correlated with regulating whole-blood viscosity, plasma viscosity, fibrinogen, thromboxanes B2, and CRP level. However, future well-designed prospective, randomized, double-blind placebo-controlled trials with large sample sizes are required to evaluate the evidence.

show abstract

Section: Introductionmentioning

confidence: 99%

Dazhu Hongjingtian Preparation as Adjuvant Therapy for Unstable Angina Pectoris: A Meta-Analysis of Randomized Controlled Trials

2020

View full text Add to dashboard Cite

show abstract

“…How to cite this article: Ibrahim DA: Dyslipidemic and protective effects of aspirin and clopidogrel in obese rats. Int J Pharm Sci & Res 2018; 9(9): 3647-55. doi: 10.13040/IJPSR.0975-8232.9 (9).3647-55.…”

Section: Conflict Of Interestmentioning

confidence: 99%

“…Clopidogrel is approved for prevention of atherosclerotic events following recent myocardial infarction, stroke, and established peripheral arterial disease. Additionally, it is also used for preventing ischemic heart disease and as prophylaxis of thrombotic events in acute coronary syndrome (unstable angina) 9 .…”

Section: Introductionmentioning

confidence: 99%

Untitled

2018

IJPSR

View full text Add to dashboard Cite

Introduction: Antiplatelets play a crucial role in improving many metabolic disorders and complications, including dyslipidemia, atherosclerosis, diabetes mellitus and cardiovascular diseases. The most common and effective antiplatelets used widely are aspirin and clopidogrel. The aim of this study is to evaluate the dyslipidemic and protective effects of aspirin and clopidogrel in obese rats. Materials and methods: 24 rats were divided into two groups, control (n = 6) (was taken normal chow) and the other group (n = 18) were allowed to eat beef tallow (90 g) and saturated fat (10 g) for 6 weeks to induce obesity. The second group was further classified to three subgroups, subgroup I (n = 6) was kept as obese group (n = 6) (positive control), subgroup II (n = 6) obese rats were treated with aspirin and subgroup III (n = 6) obese rats were treated with clopidogrel for 7 days. At the end of experiment blood samples were taken and lipid profile, FBS measured as well as body weight and the relative weights of liver were calculated. Histopathological samples were taken from different organs including liver, kidneys and heart. Results: Outcomes of this study showed that both tested drugs had dyslipidemic and protective effects as they significantly reduced cholesterol, TG, FBS as well as body and liver weight. They also ameliorated obesity-induced abnormalities in histopathological tissues with slight differences between the tested groups. Conclusion: It suggested from the findings of this study that both aspirin and clopidogrel might have dyslipidemic and protective effects in obese rats supported by histopathological findings.

show abstract

“…The prevalence of cardiovascular diseases (CADs) in China is still rising based on a recent report [ 2 ]. ACS has been stratified into ST-elevation myocardial infarction (STEMI) and non-ST elevation ACS (NSTEACS); the latter is further classified into non-STEMI (NSTEMI) and unstable angina (UA) according to cardiac biomarkers of necrosis, such as cardiac troponin [ 3 , 4 ].…”

Section: Introductionmentioning

confidence: 99%

Associations between circulating IgG antibodies to Apolipoprotein B100-derived peptide antigens and acute coronary syndrome in a Chinese Han population

Zhang

Han

et al. 2018

Bioscience Reports

View full text Add to dashboard Cite

Objectives: Acute coronary syndrome (ACS) is the major cause of mortality worldwide and caused mainly by atherosclerosis of coronary arteries. Apolipoprotein B100 (ApoB100) is a major component of low-density lipoprotein (LDL) and its oxidation can trigger inflammation in vascular endothelial cells leading to atherosclerosis. The association between antibodies to ApoB100-derived antigens and atherosclerotic diseases has been studied in recent years, but the findings appear to be controversial. The present study developed an ELISA in-house with ApoB100-derived peptide antigens to circulating anti-ApoB100 IgG antibodies in patients with ACS. Methods: Fifteen ApoB100-derived peptide antigens (Ag1–Ag15) were designed to develop an in-house ELISA for the detection of circulating anti-ApoB100 IgG levels in 350 patients with ACS and 201 control subjects amongst a Chinese population. Binary logistic regression was applied to examine the differences in anti-ApoB IgG levels between the patient group and the control group with adjustment for a number of confounding factors; the correlation between anti-ApoB100 IgG levels and clinical characteristics was also tested. Results: Patients with ACS had significantly higher levels of plasma IgG for Ag1 (adjusted P<0.001) and Ag10 antigens (adjusted P<0.001). There was no significant increase in the levels of IgG to the other 13 antigens in these ACS patients. In the control group, anti-Ag10 IgG levels were positively correlated with age, high-density lipoprotein (HDL), and ApoA levels (P≤0.001 for all) and negatively correlated with blood triglyceride (TG) (P=0.008); in the patient group, anti-Ag10 IgG levels were positively correlated with LDL (P=0.003), and negatively correlated with ApoA (P=0.048) and systolic blood pressure (SBP) (P=0.036). The area under ROC (receiver operator characteristic) curve (AUC) was 0.612 (95% confidence interval (CI): 0.560–0.664; P<0.001) in anti-Ag1 IgG assay and 0.621 (95% CI: 0.569–0.672; P<0.001) in anti-Ag10 IgG assay. Conclusion: Circulating IgG for ApoB100-derived peptide antigens may be a useful biomarker of ACS, although anti-ApoB IgG levels were not associated with the coronary artery plaque burden characterized by the coronary Gensini score.

show abstract

Acute management of unstable angina and non-ST segment elevation myocardial infarction

Cited by 21 publications

References 32 publications

Dazhu Hongjingtian Preparation as Adjuvant Therapy for Unstable Angina Pectoris: A Meta-Analysis of Randomized Controlled Trials

Dazhu Hongjingtian Preparation as Adjuvant Therapy for Unstable Angina Pectoris: A Meta-Analysis of Randomized Controlled Trials

Untitled

Associations between circulating IgG antibodies to Apolipoprotein B100-derived peptide antigens and acute coronary syndrome in a Chinese Han population

Contact Info

Product

Resources

About